EGFR and neoplasm: Accordingly, in one study of a representative triple-negative European population, EGFR >50% assessed in the primary tumour (n = 284) was associated with a 2-fold increase in the risk of recurrence and death (HR for 4-year DFS 2.39, 95% CI 1.32–4.34, p = 0.004 and for OS, HR 2.34, 95% CI 1.2–4.9) (58).